cyrilzakka/clinical-trials huggingface dataset:
Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results.

The general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrated contribution of several genomic markers (Genome Wide Association study, GWAs), new clinical and analytical variables (human exposome concept) and gender perspective to the prediction of response to the intervention at 12 month and its long-term longitudinal maintenance (3 years). The investigators intend, therefore, to provide new evidence to advance towards precision medicine. The investigators will focus our attention also on identifying those patients who, after being classified at the weight loss nadir as responders experienced weight regain.


Eligibility Criteria:
Inclusion Criteria:

* Men and women between the ages of 18 and 65 at the time of surgery
* SG or RYBP as bariatric procedure.
* With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI\>40.0 kg/m2 at the time of surgery.
* Provision of an informed consent form signed and personally dated by the patient.
* With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).

Exclusion Criteria:

* Any previous gastrointestinal surgery
* Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS
* End stage kidney disease (eGFR \<15 ml/min/1.73m2) or liver cirrhosis at baseline
* Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer)
* Known type 1 diabetes or LADA diabetes
* Women who become pregnant during the follow-up period
* Current drug or alcohol abuse
* Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.
Effect of Platelet-Rich-Plasma in Spine Fusion

The objective of this study is to evaluate the fusion rate after the use of platelet rich plasma with autolgus bone graft and comparing it with bone graft alone

The study will be submitted for approval by the Ethics Committee of Faculty of Medicine, Assiut University, and written informed consent will be obtained from all patients prior to enrollment. The study population will be selected from patients attending the Department of Orthopedics and Trauma surgery, Assiut University hospitals.

A total of 104 patients treated with single level degenerative or lytic lumbar Spondylolisthesis indicated for PLF will be included ,patients will be classified into 2 groups Group A:Of 52 patients PLF + autologus bone graft+ PRP Group B: Of 52 patients treated with PLF + autologus bone graft only without adding PRP

Methods of evaluation

* History taking.
* Full clinical and neurological examination
* Radiological evaluation by x-ray (antero posterior, lateral, and, CT scans provide excellent views of bony detail) and MRI if needed Method of randomization By shuffling cards method the candidate patient will choose one card from104 cards 52 of them containing fusion with PRP and the other 52 contaning Fusion without PRP

Platelet-rich plasma (PRP is obtained using a two-stage centrifugation process:

Whole blood sample will be drawn from the participant and be collected in a sterile tube containing anticoagulant (sodium citrate 3.8% or Ethylenediaminetetra acetic acid). The tube will be centrifuged at 160xg relative centrifugal force (about 1000 round per minute) for 10 min in a centrifugal apparatus. The first spin will separate platelet poor plasma at the top from red blood cells at the bottom and platelet rich plasma above (mixed with the white blood cells in the buffy coat). The Platelet poor plasma, Platelet rich plasma and a few red blood cells will be aspirated into a new tube, mixed and in the second spin, the tube will be centrifuged at 400xg relative centrifugal form (about 1500 round per minute) for another 10 minutes. The upper section will consist of Platelet poor plasma and the Platelet rich plasma will be collected at the bottom of the tube in the form of pellet. Then, Platelet poor plasma and Platelet rich plasma will be aspirated and mixed (discarding the upper portion). Prior to treatment calcium chloride 3% will be added to activate platelets specimen

Eligibility Criteria:
Inclusion Criteria:

degenerative or lytic Spondylolisthesis.

Degenerative disc disease requiring posterior lumbar fusion not responding to medical treatment for 1 year.

Age between 20 \& 75 years.

Single level fusion

Exclusion Criteria:

Multiple levels patient Traumatic Spondylolisthesis Previous lumbar spine surgery. Other lumbar spine pathology severe osteoporosis Patients younger than 20 years old. Patients older than 75 years old. Immunocompromised patients (eg. Chronic renal failure)
Aromatherapy for Postoperative Nausea and Vomiting in Children

Postoperative nausea and vomiting (PONV) is one of the most common postoperative complications of general anesthesia in pediatrics. Pediatric rates of nausea and vomiting are approximately double those of adult patients. Aromatherapy has recently been shown to reduce PONV in adults, but the effect in paediatric patients is unknown. The goal of this study is to determine the feasibility of a large-scale study in the paediatric population.

Postoperative nausea and vomiting (PONV) is one of the most common postoperative complications of general anesthesia occurring after up to 40% of general anesthetics. PONV is an unpleasant experience and can result in secondary complications including wound dehiscence, electrolyte abnormalities and aspiration pneumonia. PONV often causes delayed stays in the postanesthesia care unit and delayed hospital discharge.

The mechanism of PONV is poorly understood. Given the multifactorial nature of nausea and vomiting, standard pharmacological therapy approaches the problem from various pathways. Methods that include antihistaminic therapies such as dimenhydrinate (gravol), antiserotonergic medications such as ondansetron (Zofran) and glucocorticoids (dexamethasone), have been used effectively in different surgical settings to address PONV. They do not work however, without occasional significant side effects such as urinary retention, blurred vision, increased infection rates, headaches and constipation. Given that pharmacological interventions for PONV are not universally effective and have accompanying side effects, there has been recent interest in additional complementary interventions.

Aromatherapy has been used to treat nausea from motion sickness, pregnancy, cancer and pain. In postoperative adults, a recent large adequately powered randomized control trial found aromatherapy resulted in a significant risk reduction of nausea (0.37) when compared with saline. Given the encouraging results of the first adequately powered adult study, the goal is to determine whether PONV is reduced by aromatherapy in the pediatric population. Thus, the primary aim of this study is to determine if aromatherapy is more effective than placebo in the treatment of postoperative nausea in children as a complementary treatment to current postoperative practices.

This research is important as it is the first study to assesses whether aromatherapy can be useful in postoperative nausea treatment for children. The implications of this study could mean an improvement in the health care experience of children who have nausea postoperation and potentially a reduction in rescue antinausea drug use in this population in the future.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) class I or II
* absence of neurodevelopment disorders
* patient having elective day surgery

Exclusion Criteria:

* family or patient refusal
* allergy or sensitivity to aromatherapy oils
* inability to smell in the postoperative period
Evaluate Dental Plaque Benefit of a Preventive Treatment Gel

The objective of the study is to evaluate anti-plaque efficacy of a preventive treatment gel in a modified 4-day plaque model.


Eligibility Criteria:
Inclusion Criteria:

* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
* Be 18 years of age or older;
* Agree not to participate in any other oral/dental product studies during the study;
* Agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed;
* Agree to refrain from the use of any non-study oral hygiene products (subjects who are regular flossers will be allowed to floss during acclimation and wash-out periods);
* Agree to use an oral hygiene product that contains stannous fluoride;
* Agree to refrain from any form of non-specified oral hygiene during the treatment period, including the use of products such as floss, toothpicks for plaque removal, and chewing gum;
* Agree to refrain from any oral hygiene, eating and drinking after 11:00 PM the evening before plaque measurements on Day 0 and Day 4 of the treatment periods;
* Agree to return for all scheduled visits and follow study procedures;
* Possess a minimum of 20 natural teeth with scorable facial and lingual surfaces, of which at least 4 are molars; and,
* Be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study.

Exclusion Criteria:• Have a medical condition requiring pre-medication prior to dental procedures;

* Have taken antibiotics within 2 weeks of the acclimation period or anticipate taking antibiotics at any time during the study;
* Have a history of allergies or hypersensitivity to dyes or dentifrices that contain stannous fluoride;
* Have removable or orthodontic appliances which interfere with obtaining 20 gradable teeth;
* Have previously demonstrated an inability to comply with study visit requirements;
* Have rampant caries, open or untreated caries, severe gingivitis or advanced periodontitis requiring prompt treatment; or,
* Present with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study.
The Satiating Effect of Eggs in Children

This study will determine which breakfast (egg breakfast or bagel breakfast) has the most beneficial effect on appetite.

Test Day 1 (about 4 hours)

* This is a fasting visit (nothing besides water 12 hours prior to visit)
* Your child will be offered one of two breakfasts (egg breakfast or bagel breakfast)

  . He/she will be asked to eat all the food that is provided.
* He/she will be asked to rate the taste of the meal.
* He/she will be offered a pasta lunch.

Test Day 2 (about 4 hours)

* This will be scheduled 1 week after Test Day 1
* This is a fasting visit (nothing besides water 12 hours prior to visit)
* The procedures for this visit are the same as for Test Day 1. Your child will be offered the breakfast that he/she did not receive at the last visit.

The sequence of the 2 breakfasts will be randomly assigned to each child.

Eligibility Criteria:
Inclusion Criteria:

* • Is a healthy boy or girl between 14 and 17 years of age

  * Is a healthy boy or girl between 4 and 6 years of age

Exclusion Criteria:

* • Is suffering from any diseases such as major heart conditions, type 1 diabetes, cancer, eating disorders, or any serious illness that requires intensive and long-term medical treatment

  * Has allergies/sensitivities/dislikes to eggs, soy, or wheat
  * Uses drugs recreationally
  * Is actively attempting to lose weight
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).

* There are three phases of treatment 1)chemoradiation, 2) consolidation and 3)maintenance therapy.
* The chemoradiation phase is from week 1 to week 7. The following will occur during this phase: Daily chest radiation starting on day 1; pre-medication for paclitaxel; weekly intravenous administration of paclitaxel and carboplatin; intravenous administration of bevacizumab once weekly every three weeks starting on day 1.
* During weeks 8-9, patients will undergo a PET/CT scan for restaging.
* The consolidation phase is from week 10 to week 16. The following will occur during this phase: Pre-medication for paclitaxel; intravenous administration of paclitaxel and carboplatin twice weekly every 3 weeks; intravenous administration of bevacizumab once weekly every 3 weeks.
* The maintenance phase is from week 17 to week 52. The following will occur during this phase; intravenous administration of bevacizumab once a week every three weeks for 1 year; PET/CT scan every three months.
* The following evaluations will occur during treatment: 1)Patients will be evaluated weekly by the study doctor, 2) Weight, difficulty or discomfort in swallowing, shortness of breath and over well-being will be recorded, 3) Weekly lab test will include CBC, chemistries, and liver function tests. 4) Followed through each cycle of chemotherapy and every 6-8 weeks for the duration of the study.
* The following evaluations will occur after treatment: 1)Every 6-8 weeks assessed for response with a CT or PET/CT scan for one year, 2) Toxicity will also be assessed at each follow-up interval.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed non-small cell lung cancer (NSCLC) that have been evaluated and determined not to be candidates for surgical resection as part of their definitive management of stage III disease.
* Age 18 years or older
* ECOG performance status of 0-1
* Life Expectancy of greater than six months
* Normal organ and marrow function
* Women and men of child-bearing potential must agree to use adequate contraception

Exclusion Criteria:

* Prior chemotherapy or thoracic radiation therapy
* Squamous histology or any histology in close proximity to a major vessel
* Active hemoptysis
* History of hypercoagulability
* Known distant metastatic disease
* History of allergic reactions attributed to compounds with similar chemical or biological composition to bevacizumab, carboplatin, paclitaxel or other agents used in this study
* Patients with uncontrolled intercurrent illness
* Pregnant women
* Major surgical procedure, open biopsy, or significant traumatic injury with in 28 days prior to day 0
* Minor surgical procedure within 7 days to day 0
* HIV-positive patients receiving combination anti-retroviral therapy.
* Non-skin cancer malignancy in the past 5 years.
The Effect of Breastfeeding Support on Exclusive Breastfeeding, Occurrence of Breast Problems and Breastfeeding Self-Efficacy

The aim of the study is to determine the effect of individual breastfeeding support on the lactation process. The research is a randomized controlled experimental study. The sample of the study consisted of pregnant women who applied to the Obstetrics Polyclinic of a university hospital (intervention=51, control=51). In the study, individual breastfeeding education was given to the intervention group during the antenatal period, and a training booklet was given to the control group. In the postpartum period, home visits and phone follow-ups were carried out for both groups between the fifth day and the sixth month. The effect of breastfeeding counseling on the lactation process; The duration of exclusive breastfeeding, breast problems and breastfeeding success was evaluated with. The data of the study were collected using the Pregnant, Postpartum-Newborn Information Form, Breastfeeding Questionnaire, Breast Problems Diagnosis Form, LATCH Breastfeeding Diagnostic Tool and Breastfeeding Self-Efficacy Scale.


Eligibility Criteria:
İnclusion Criteria:

* Open communication and collaboration
* Over 18 years of age
* Having a singleton pregnancy
* Never given birth,
* At least in the 35th week of gestation,
* Residing in Manisa Central districts (Yunusemre and Şehzadeler),
* There is no maternal obstacle that would affect breastfeeding,
* Having no vision or hearing problems,
* Those who are willing to participate in the study

Exclusion Criteria:

* At the beginning of the research;
* Under 18 years of age,
* Having a risky pregnancy,
* Having breastfeeding experience,
* Less than the 35th gestational week,
* Residing outside Manisa Central districts (Yunusemre and Şehzadeler),
* Any maternal disability that may affect breastfeeding,
* Pregnant women who did not want to participate in the study were excluded.

During the research process;

* Those who want to leave the job,
* If the baby has any obstacle that may affect breastfeeding (presence of anomaly, stay in intensive care, etc.),
* Cannot be reached within the first 5 days after birth,
* Mothers who changed their residence to live in another city/district other than Manisa Central districts (Yunusemre and Şehzadeler) were excluded from the study.
Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion

This study intends to investigate the efficacy and safety of medical thoracoscopic cryotherapy combined with standard first-line treatment of advanced non-small cell lung cancer with malignant pleural effusion through a randomized controlled clinical trial.


Eligibility Criteria:
Inclusion Criteria:

1. 18-75 years old;
2. Non-small cell lung cancer with pleural metastasis confirmed by histopathology or cytology;
3. ECOG score 0-1;
4. Cardiopulmonary function can tolerate painless thoracoscopic examination;
5. Patients who underwent medical thoracoscopy for pleural effusion at first diagnosis and underwent medical thoracoscopy cryotherapy at the same time of biopsy were also included in the study. Non-small cell lung cancer was confirmed by pathological results;
6. All subjects or their guardians must sign the informed consent before entering the study.

Exclusion Criteria:

1. Expected survival \<2 months;
2. Hemoglobin \<110g/L, white blood cell count \<3×109/L, neutrophil \<2.0×109/L, platelet \<100×109/L;
3. severe cardiac insufficiency, abnormal liver and kidney function (blood test results of transaminase and creatinine \> 1.5 times the normal upper limit);
4. have received chemotherapy or anti-angiogenic drugs (such as bevacizumab, endu, anlotinib, etc.);
5. History of radiotherapy;
6. history of intrathoracic local treatment;
7. multiple serous cavity effusion, or bilateral pleural effusion;
8. patients allergic to erythromycin;
9. the lung cannot be reopened.
Thyme Honey for Management of Oral Lichen Planus

the study aimed to assess the effect of topical application of thyme honey in comparison to 0.1% triamcinolone acetonide oral paste on the relief of pain and clinical improvement in patients with OLP


Eligibility Criteria:
Inclusion Criteria:• Patients clinically and histopathologically (if required) diagnosed as suffering from OLP.

* Patients free from any visible oral lesions other than OLP.
* Patients who agreed to take supplied medications.
* Patients who agreed for the biopsy (when required).

Exclusion Criteria:• •Patients suffering from any systemic disease.

* Treatment with any systemic treatment such as systemic steroids, other immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks.
* Treatment with any oral topical medications for at least four weeks prior to the study.
* Pregnant and lactating women.
* In addition, no consideration was given to patients with a history of hypersensitivity to honey.
Early Diagnosis of Premature Births by Analysis of the Vaginal Microbiota

Objectives: to assess the relevance of the RiboTaxa algorithm coupled with neural network learning based on analysis of vaginal microbiota metagenomic sequencing data for predicting prematurity in an identified at-risk population.

Study description: Longitudinal follow-up of a cohort of pregnant women, with collection of biological samples, and a posteriori case-control comparison based on the occurrence of an event (premature birth).

There is currently no reliable clinical or biological diagnosis to predict premature birth. Recent work using metagenomic data analysis coupled with artificial intelligence approaches suggests that there may be a vaginal microbiota signature during pregnancy that correlates with the occurrence of preterm birth. The aim of the study is to use biological samples to confirm the identification of these vaginal microbiota signatures as a means of predicting preterm birth.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women Admitted to the Clermont-Ferrand University Hospital maternity ward from 14 weeks' gestation onwards
* For threat of preterm birth (PTB) characterized by contractile activity and/or cervical changes, or for premature rupture of fetal membranes (PROM)
* And in need of vaginal swabbing
* Single or multiple pregnancy
* Able to understand and object to the study
* Covered by a French social security scheme.
* Give informed consent for the study

Exclusion Criteria:

* Patient under guardianship, curatorship or safeguard of justice
* Patient having received antibiotic therapy in the 2 weeks prior to admission